I want to thank you for being a keen reader and subscriber to ChinaBio Today, but just as the biopharma landscape is changing, so are we.

For 17 years, we have brought you news on the rapidly evolving life science industry in China and the wider Asia-Pacific region through ChinaBio Today. Now, with ChinaBio Today’s editor Richard Daverman on board, we intend to continue the journey to report these deals and trends in our brand-new publication BioXconomy.

BioXconomy is the official media partner for Informa Connect Life Sciences partnering events, which now includes ChinaBio Partnering Forum and ChinaBio Investor Forum among the flagship LSX, EBD Group, and partneringONE brands.

The APAC region will become a major focus amid our year-round coverage of life sciences investment, innovation, partnerships, and business strategies within the virtual pages of BioXconomy. Along with our regular “Eyes on Asia” dealmaking round-up, we will strive to bring you an insider’s look into some of the bigger stories and rumblings within China and beyond.

ChinaBio Today will remain available as an archive, but going forward subscribe to the BioXconomy newsletter here to stay abreast of movements in Asia and beyond.

Thanks again for your continued following.

Dan Stanton

Editorial director, Informa Connect Life Sciences

• Regor Pharma, a Shanghai-Boston biotech, received $850 million upfront from Genentech for global rights to two early-stage CDK inhibitors aimed at breast cancer;
• Kailera Therapeutics launched with a four-drug pipeline from Hengrui aimed at obesity; Keilera was formed by four US VCs who funded the startup with an initial $400 million;
• Caliway Biopharma staged a record-high IPO for a biotech company on the Taiwan Exchange, raising $206 million at a $3 billion valuation for its targeted weight loss candidate;
• Flagship Pioneering, a Cambridge, MA company, formed a collaboration with Singapore’s A*STAR to back new Singapore-based health companies;
• Hong Kong’s GenEditBio received a strategic investment from Gobi Partners GBA to develop affordable "precision DNA surgery" gene therapies for genetic diseases.
  
  Share this with colleagues:  
  
  

Deals and Financings

• Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy from Capricor of San Diego in a $735 million deal;
• Shanghai’s Fosun Pharma will pay $37 million to buy out its JV partner, Kite Pharma, gaining full control of the JV’s two CAR-T products in China;
• Organon China acquired China rights to an ovarian stimulation therapy from Shanghai Bao Pharma for $12 million upfront plus milestones;
• Hangzhou Celregen Therapeutics raised “tens of millions RMB” to advance its stem cell regenerative medicine and cell therapy products;

Clinical Trials

• Beijing QL Biopharma broke new ground in the crowded GLP-1 marketplace with news that ZT002 was effective in a once-monthly dosing regimen.
  
  Share this with colleagues:  
  
  

Deals and Financings

• Shanghai’s EpimAb sold global (ex-China) rights for a clinical-stage BCMA-targeting T-cell engager to Vignette Bio, a San Francisco startup, in a $635m deal.
• Shenzhen TargetRx raised $20m by selling China commercial rights for an ALK inhibitor to Nanjing’s Simcere Zaiming;
• Hangzhou Hygieia Biotech staged an A2 financing to advance its 11 siRNA molecules, including two out-licensed assets, one with Fosun the other with Tasly;

Company News

• Connect Biopharma has moved its headquarters to San Diego from Suzhou; it sold China rights for its lead asset, rademikibart, to Simcere and wants another deal for the rest of the world.
  
  Share this with colleagues:  
  
  

Deals and Financings

• Belgium’s UCB divested its entire current China five-drug portfolio, making way for its late-stage clinical assets; CBC paid $680 million for the older drugs;
• Shanghai’s YolTech sold China rights for its PCSK9-targeting base editing therapeutic to Shenzhen Salubris Pharma in a $145 million deal;
• New Jersey’s Navigator Medicines raised $100 million in initial funding to develop an OX40L-targeted portfolio in-licensed from Korea’s IMBiologics;
• Bora Pharmaceuticals, a Taiwan CDMO, continued its acquisition of US-based CDMOs by acquiring a 30.5% share of San Diego’s Tanvex Biopharma;
• Shanghai DualityBio plans to conduct a Hong Kong IPO to support its portfolio of ADC therapeutics for cancer and autoimmune diseases.
  
  Share this with colleagues: